TCL Archive A Message From NCI: “We Deeply Regret The Need To Eliminate This Program.” AP4 Applicants And Corporate Partners Spent Years, Money, Before NCI Pulled The Plug On Novel Public-Private Partnerships. Von Eschenbach Called AP4 “A New Paradigm” For Drug Development. NCI Executive Committee “Prioritized” Programs. April 21, 2006
TCL Archive Congressional Panel Is Investigating FDA Oversight Of Generic Cancer Drugs August 18, 1995
TCL Archive In Brief: ACCC to Bid On Ovarian Cancer Treatment RFP; Community MDs Handle 90% Of Ovarian Patients September 5, 1975
TCL Archive IOM Review Of Duke Genomics Trials To Focus On Validation, Scientific Criteria October 22, 2010
